Avidian Announces Resignation of a Director
TORONTO, June 29, 2018 (GLOBE NEWSWIRE) -- Avidian Gold Corp. (“Avidian” or the “Company”) (TSX-V:AVG) wishes to announce the resignation of Giulio Bonifacio from the board of directors effective immediately so that he can pursue his commitments to other ventures.
The board of directors wishes to thank Giulio for his contributions to the Corporation as it progressed from a private company to a public company and wishes him the best in his future endeavours.
About Avidian Gold Corp.
Avidian Gold is a mineral exploration and development company. Avidian Gold holds a 100% interest in the Golden Zone gold-silver-copper project located halfway between Anchorage and Fairbanks, Alaska, along the State highway. The Golden Zone property hosts a NI 43-101 Indicated gold resource of 267,400 ounces (4,187,000 tonnes at 1.99 g/t Au) plus an Inferred gold resource of 35,900 ounces (1,353,000 tonnes at 0.83 g/t Au). Avidian Gold also holds a 100% interest in the Amanita gold project located adjacent to Kinross Gold’s Fort Knox mine outside of Fairbanks, Alaska as well as early stage exploration properties in Nevada (USA) and Newfoundland (Canada).
On Behalf of the Board of Directors,
Avidian Gold Corp.
“James Polson”
James Polson
CEO
For further information, please contact:
Dino Titaro
President
Avidian Gold Corp.
(647) 283-7600
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.
Forward-looking information
This News Release includes certain "forward-looking statements". These statements are based on information currently available to the Company and the Company provides no assurance that actual results will meet management's expectations. Forward-looking statements include estimates and statements that describe the Company's future plans, objectives or goals, including words to the effect that the Company or management expects a stated condition or result to occur. Forward-looking statements may be identified by such terms as "believes", "anticipates", "expects", "estimates", "may", "could", "would", "will", or "plan". Since forward-looking statements are based on assumptions and address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results relating to, among other things, results of exploration, project development, reclamation and capital costs of the Company's mineral properties, and the Company's financial condition and prospects, could differ materially from those currently anticipated in such statements for many reasons such as: changes in general economic conditions and conditions in the financial markets; changes in demand and prices for minerals; litigation, legislative, environmental and other judicial, regulatory, political and competitive developments; technological and operational difficulties encountered in connection with the activities of the Company; and other matters discussed in this news release. This list is not exhaustive of the factors that may affect any of the Company's forward-looking statements. These and other factors should be considered carefully and readers should not place undue reliance on the Company's forward-looking statements. The Company does not undertake to update any forward-looking statement that may be made from time to time by the Company or on its behalf, except in accordance with applicable securities laws
This news release does not constitute an offer of securities for sale in the United States. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and such securities may not be offered or sold within the United States absent U.S. registration or an applicable exemption from U.S. registration requirements.
© 2018 GlobeNewswire, Inc. All Rights Reserved.
Hepion Pharmaceuticals' (Nasdaq: HEPA) CRV431 Prevents Cirrhosis in Experimental Model of Severe Liver Disease
